1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

The Factory Floor: Suanfarma Expands API Capacity With Sandoz Deal In Italy

Meanwhile, Glenmark, Aurobindo And Cipla Have Run-ins With The FDA.

 
• By Akriti Seth

Suanfarma acquires an API manufacturing facility in Italy to accelerate its growth in Europe, while CapsCanada relocates its headquarters as part of its growth strategy. Meanwhile, Glenmark, Aurobindo and Cipla struggle with quality issues.

Scientist_Lab
The latest growth initiatives and quality control measures in the pharma space • Source: Shutterstock

Suanfarma Group has struck a deal with Sandoz Industrial Products to acquire an active pharmaceutical ingredient manufacturing facility in Rovereto, Italy. With this new acquisition Suanfarma expects “to reach €300m ($330m) turnover by 2020.”

Héctor Ara, president of Suanfarma, said “we are impressed by the know-how at the Rovereto site and intend to leverage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Business

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)

Biocon Agreement Provides Multiple Oncology Biosimilars To Malaysian Cancer NGO

 
• By Dean Rudge

Biocon Biologics will look to combine its “scientific expertise with the National Cancer Society of Malaysia’s strong community outreach and patient support network,” after signing striking up a partnership with the NGO providing for supply of three biosimilars.

EMA Greenlights Give Eylea And Stelara Biosimilars Momentum Across Europe

 
• By Dean Rudge

The EMA’s Committee for Medicinal Products for Human Use has issued positive opinions for multiple aflibercept and ustekinumab biosimilars, intensifying competition for Eylea and Stelara respectively in Europe. Meanwhile, a Biocon subsidiary also received a nod for a Neulasta biosimilar.